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There are a lot of convincing evidences about the involvement of endothelin pathway proteins in the pathogenesis of atherosclerosis
and its fatal complications. In this study, the analysis of a possible association between EDN1 rs5370 and EDNRA rs5335 gene
polymorphisms and the risk of large artery stroke (LAS) in a Ukrainian population was conducted. 200 LAS patients and 200
unrelated controls were enrolled in a case-control study. The polymerase chain reaction-restriction fragment length
polymorphism method (PCR-RFLP) was used for SNP genotyping. Our results revealed that EDN1 rs5370 polymorphism was
associated with LAS development both before and after adjustment for atherosclerosis risk factors (sex, age, body mass index,
arterial hypertension, type 2 diabetes mellitus, and smoking). The risk for a LAS incident in rs5370-T allele carriers was 1.6
times higher (CI = 1.066–2.403; P = 0 020) than in subjects with the GG genotype. No link between EDNRA rs5335 and LAS risk
in a Ukrainian population was found. The present study indicated that EDN1 rs5370, but not EDNRA rs5335, can be the strong
genetic predictor for LAS development in a Ukrainian population.
1. Introduction
As it is well known, endothelial dysfunction plays an
important role in the development of common cardiovascu-
lar diseases and their complications [1]. One of the main
pathogenetic pathways of endothelial dysfunction develop-
ment is an increased formation and biological activity of
the powerful vasoconstrictor and proinflammatory peptide
endothelin (ET-1) [2], which mediates own effects via
two pharmacologically distinguishable receptor subtypes,
endothelin A (ETA) and endothelin B (ETB) receptors,
respectively [3]. There are several lines of evidence indicating
that the ET-1-induced endothelial dysfunction is realized
through decreasing production and increasing degradation
of NO, through enhancement of Von Willebrand factor
and reactive oxygen species formation, and also through the
activation of proinflammatory metabolic pathways in the
endotheliocytes [4].
In recent years, a wide range of case-control studies to
test the association between various single nucleotide poly-
morphisms (SNPs) of the ET-1 (EDN1) and its receptor
(EDNRA and EDNRB) genes and development of arterial
hypertension (AH) [5, 6], pulmonary hypertension [7],
myocardial infarction [8], diabetic retinopathy [9] and
nephropathy [10], metabolic syndrome [11], and hemor-
rhagic stroke [12] have been carried out. There are several
works that concern the investigation of the effect of EDN1,
EDNRA, and EDNRB genetic polymorphisms on ischemic
stroke (IS) development. Zhang and Sui showed that
rs5370-T allele (EDN1 gene) increased the IS incidence risk
in Northern Han men, whereas the rs5335-CC genotype
(EDNRA gene) had a protective effect in the same popula-
tion [13]. Yamaguchi et al. revealed a significant association
between EDN1 rs5370 polymorphism and high risk for IS
only among Japanese women [14], whereas Aslan et al.
and Gormley et al. did not find any relation between the
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mentioned SNP and stroke morbidity among the Turkish
[15] and English [16] population, respectively. Thus, the data
obtained in different populations are contradictory, which
requires further study about the role of polymorphic variants
of the endothelin family genes in the IS development.
The aim of the present case-control study was to investi-
gate the possible association between EDN1 rs5370 and
EDNRA rs5335 polymorphisms and large artery stroke
(LAS) in representatives of the Ukrainian population.
2. Materials and Methods
2.1. Study Population. Venous blood of 200 unrelated
Caucasians (Ukrainians) with LAS (89 females and 111
males; mean age [±SD] 66 7 ± 10 1) and 200 control subjects
(75 females and 125 males; mean age 68 1 ± 13 9) was used
for the study. Each stroke patient had been under dispensary
observation in the 5th Sumy Clinical Hospital since April
2009 to December 2017. Computed tomography and (or)
magnetic resonance imaging investigations of the head as
well as electrocardiographic, biochemical, and coagulation
tests and carotid ultrasonography were used for final LAS
diagnosis establishment. The pathogenic variant of IS was
determined according to the TOAST criteria [17]. Individ-
uals with cardioembolic, lacunar, and hemorrhagic strokes,
traumatic brain injury, and brain tumors were excluded.
The clinical characteristics of LAS patients included systolic,
diastolic, pulse and mean arterial blood pressure (BP),
body mass index (BMI), lipid profile parameters, and coa-
gulogram indices.
Only participants without the history of IS or other acute
cerebrovascular pathologies, myocardial infarction, and
other atherosclerosis complications were enrolled to the con-
trol group. Subjects of the comparison groups were divided
into subgroups defined by sex and the presence or absence
of AH (systolic BP> 140mmHg, diastolic BP> 90mmHg,
or both). The study protocol complied with the Declaration
of Helsinki and was approved by the Ethic Committee of
the Medical Institute of Sumy State University (number
2/02.17.09). An appropriate written informed consent was
obtained from all individuals.
2.2. Genotyping of SNPs. Genomic DNA was isolated from
peripheral leukocytes using GeneJET Whole Blood Genomic
DNA Purification Mini Kit (Thermo Fisher Scientific, USA).
Polymerase chain reaction-restriction fragment length poly-
morphism analysis (PCR-RFLP) was used for genotyping
EDN1 rs5370 and EDNRA rs5335 SNPs. The reaction
mixture for PCR (total volume 25μL) included 2mM
MgSO4, 0.2mM dNTPs (Thermo Fisher Scientific, USA),
5μL 5×PCR buffer, 1U Taq DNA polymerase (Thermo
Fisher Scientific, USA), and 75–100ng DNA. The nucleotide
structure of the primers and PCR conditions, which were
used for each polymorphism investigation, are shown in
Table 1. PСR was carried out in Thermocycler GeneAmp
PCR System 2700 (Thermo Fisher Scientific, USA).
2U of Сас81 (Thermo Fisher Scientific, USA) was used
for restriction analysis of EDN1 rs5370 polymorphism
(incubation at 37°C for 17 h). The presence of guanine at
the 5665th position of the EDN1 gene led to the cleavage of
the amplicon (262 bp) by Cac81 into two parts of 189 and
73 bp. In the case of guanine to thymine replacement, we
had only one 262 bp fragment due to the loss of the Cac81
catalytic site (Figure 1). Restriction analysis of EDNRA
rs5335 SNP required using 3U of NmuCI (Tsp45I) (Thermo
Fisher Scientific, USA) (incubation at 37°C for 19 h). The
presence of cytosine at the 70th position of the EDNRA
3′-untranslated region (3′-UTR) allowed NmuCI to cut
the primary amplicon (174 bp) into two fragments of 116
and 58 bp. Cytosine to guanine substitution resulted in
preventing the restriction and preservation of the original
174 bp fragment (Figure 2). Horizontal electrophoresis
Table 1: PCR conditions for EDN1 rs5370 and EDNRA rs5335 genotyping.







°С (60 s) 61°С (60 s) 72°С (45 s) 262 bp
EDNRA rs5335
F: 5′-TAGAAGCACTCCTCGGTACTCC-3′
R: 5′-TCG TAGATGTTGTGGGTGGATA-3′ 94
°С (50 s) 60°С (40 s) 72°С (60 s) 174 bp
Annotation: F: forward; R: reverse; D: denaturation; H: hybridization; E: elongation; bp: base pairs.








Figure 1: Results of EDN1 rs5370 polymorphism restriction analysis. M—molecular marker (bp—base pairs); lanes 3, 4, 5, and 8—GG
genotype; lanes 6, 7, 10, and 11—GT genotype; lanes 1, 2, and 9—TT genotype.
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(10V/cm) in 2.5% agarose gel (10mg/mL ethidium bro-
mide) with subsequent ultraviolet visualization was used
for restriction fragment detection.
2.3. Statistical Analysis. The Statistical Package for Social
Science software (SPSS, version 17.0, Chicago, IL, USA)
was used for most statistical analyses. Continuous variables
are presented as the mean± SD (checking the normality of
distribution was performed using Shapiro-Wilk test); cate-
gorical variables are presented as absolute number and per-
centage value. Two-tailed Student’s t-test and ANOVA with
subsequent Bonferroni post hoc test were used for compari-
son of the mean values between two or more different patient
groups. In order to control type 1 error, multiple adjust-
ment using false discovery rate (FDR)methodwasperformed.
Statistical power analysis was done using Quanto. Hardy-
Weinberg equilibrium testing was carried out using Online
Encyclopedia for Genetic Epidemiology Studies (http://www.
oege.org/software/hardy-weinberg.html). Chi square (χ2) test
was used to compare the frequency of EDN1 rs5370 and
EDNRA rs5335 alleles and genotypes as well as other cate-
gorical variables between the control and case groups. An
odds ratio (OR) and 95% confidence interval (CI) were
obtained from logistic regression for dominant, recessive,
and additive models of inheritance. Multivariable logistic
regression was used to exclude the effect of other atheroscle-
rosis risk factors including sex, age, BMI, AH, type 2 diabetes
mellitus (T2DM), and smoking status. All statistical tests
were based on a two-tailed probability; a value of P < 0 05
was considered as significant.
2.4. Prediction Analysis. In order to uncover the functional
effects of EDN1 rs5370 and EDNRA rs5335 polymorphic
sites, web available consensus classifiers PredictSNP2 [18]
and SNPinfo were used [19]. Herewith to predict the effect
of rs5370 SNP of the EDN1 5 exon on protein function Pre-
dictSNP was used [20]. We also used SpliceAid2 tool to check
if SNP 5370 is located in splicing regulatory sequence [21].
Online miRDB resource [22] was used for microRNA target
prediction in the framework of the functional analysis of
rs5335 SNP of EDNRA 3′-UTR.
3. Results
The general characteristics of the study groups are summa-
rized in Table 2. Their detailed description was presented in
our previous article [23].
The distribution of EDN1 rs5370 and EDNRA rs5335
alleles and genotypes in comparison groups is shown in
Table 3. Obtained genotype frequencies for each SNP did
not significantly deviate from Hardy-Weinberg equilibrium
expectations (PHWE > 0 05). The frequency of EDN1 rs5370
genotypes and alleles in LAS patients significantly differed
from the control group (P = 0 006 and P = 0 002, resp.),
while the distribution of EDNRA rs5335 genotypes and
alleles was similar between case and control individuals
(P = 0 391 and P = 0 521, resp.). Statistical power analysis
indicated that the rs5370 locus had strong power
(0.689—for dominant model; 0.956—for recessive model;
and 0.991—for additive model). At the same time, rs5335
SNP had poor power (0.252—for dominant model;
0.059—for recessive model; and 0.654—for additive model).
The results of two investigated SNP genotypes’ associa-
tion with LAS are presented in Table 4. Significant associa-
tion between EDN1 rs5370 and stroke was revealed under
dominant (Pc = 0 012; ORc = 1 657, 95% CI= 1.115–2.462),
recessive (Pc = 0 007; ORc = 2 839, 95% CI= 1.331–6.057),
and additive (Pc = 0 003; ORc = 3 291, 95% CI=1.512–






Figure 2: Results of EDNRA rs5335 polymorphism restriction analysis. M—molecular marker (bp—base pairs); lanes 8 and 10—CC
genotype; lanes 1, 2, 3, 4, 5, 6, and 11—CG genotype; lanes 7 and 9—GG genotype.





(n = 200) P
Age, years 66.7± 10.1 68.1± 13.9 0.261
Sex, female/male 89/111 75/125 0.155
Body mass index, kg/m2 27.9± 3.7 27.3± 4.6 0.105
Systolic BPs, mmHg 167.9± 28.7 151.7± 22.6 <0.001
Diastolic BP, mmHg 96.0± 15.5 86.5± 11.7 <0.001
Pulse BP, mmHg 71.9± 22.4 65.2± 17.2 0.002
Mean BPs, mmHg 119.9± 17.9 108.3± 14.0 <0.001
Fasting glucose, mmol/L 6.05± 1.5 5.25± 0.7 <0.001
Total cholesterol, mmol/L 4.98± 1.46 4.75± 1.52 0.124
HDL cholesterol, mmol/L 1.01± 0.29 1.09± 0.38 0.018
LDL cholesterol, mmol/L 3.16± 1.39 2.94± 1.17 0.087
Triglyceride, mmol/L 1.67± 0.78 1.54± 0.66 0.073
Current smokers, n (%) 60 (30.0) 55 (27.5) 0.581
T2DM, n (%) 50 (25.0) 19 (9.5) <0.001
Arterial hypertension, n (%) 150 (75.0) 116 (58.0) <0.001
Categorical variables were compared by χ2 test, continuous variables by
t-test.
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7.165—for TT genotype) models of inheritance. After adjust-
ing for covariates of age, sex, BMI, AH, T2DM, and smoking
status, genotypic association of rs5370 SNP remained under
dominant (Pa = 0 020; ORa = 1 601, 95% CI=1.066–2.403),
recessive (Pa = 0 003; ORa = 3 251, 95% CI=1.492–7.084),
and additive (Pa = 0 002; ORa = 3 637, 95% CI= 1.639–
8.073—for TT genotype) models. Logistic regression analysis
for EDNRA rs5335 did not show any significant link with
LAS development neither before nor after adjustment for
atherosclerosis risk factors (P > 0 05).
The analysis of rs5370 and rs5335 genotypic association
with LAS risk in female and male subjects is presented in
Table 5. In women, significant difference for rs5370 locus
was revealed in the crude dominant (Pc = 0 021; ORc =
2 090, 95% CI=1.119–3.903) and additive (Pc = 0 034;
ORc = 2 008, 95% CI= 1.055–3.823—for GT genotype)
models, as well as in adjusted dominant (Pa = 0 014; ORa =
2 437, 95% CI=1.202–4.940) and additive (Pa = 0 042;
ORa = 2 135, 95% CI= 11.079–4.393—for GT genotype;
Pa = 0 018; ORa = 5 634, 95% CI= 1.157–27.436—for TT
genotype) models. EDNRA rs5335 SNP was not associated
with stroke development in the female subgroup (P > 0 05).
In male subjects, association of rs5370-TT genotype was
revealed regardless of adjustment under recessive (Pc =
0 007, Pa = 0.007; ORa=3.512, 95% CI=1.401–8.806) and
additive models (Pc = 0 008, Pa = 0 009; ORa = 3 535, 95%
CI= 1.377–9.076). The significant link between rs5335 poly-
morphism and LAS development in the mentioned subgroup
was absent (P > 0 05).
Due to influential role of the endothelin pathway in
hypertension development, we also investigated the associa-
tion between EDN1 and EDNRA gene polymorphisms and
ischemic stroke development in patients with and without
AH (Table 6). In nonhypertensive subjects, both SNPs were
not associated with LAS either before or after adjustment
for age, sex, BMI, T2DM, and smoking (P > 0 05). In the
hypertensive cohort, the minor T allele for the rs5370 locus
was found to be significantly more prevalent in stroke
patients. Before adjusting for covariates, positive association
was revealed under dominant (Pc = 0 045; ORc = 1 649,
95% CI= 1.011–2.689), recessive (Pc = 0 024; ORc = 3 220,
95% CI=1.164–8.903), and additive (Pc = 0 013; ORc =
3 744, 95% CI=1.322–10.607—for TT genotype) models.
After adjusting for the covariates, a significant link
between EDN1 rs5370 and LAS remained under dominant
(Pa = 0 036; ORa = 1 711, 95% CI= 1.035–2.829), recessive
(Pa = 0 008; ORa = 4 102, 95% CI=1.448–11.617), and addi-
tive (Pa = 0 004; ORa = 4 743, 95% CI=11.633–13.776—for
TT genotype) models.
Table 7 indicates the clinical characteristics of LAS
patients stratified by EDN1 rs5370 genotypes. Using the
ANOVA test, significant difference was found for diastolic
(GG—93 4 ± 14 9mmHg, GT—99 3 ± 16 2mmHg, TT—
91 7 ± 13 3mmHg; P = 0 034) BP. Nevertheless, Bonferroni
post hoc test revealed no significant difference between
patients with different genotypes (P = 0 103 for GG versus
GT; P = 0 087 for GT versus TT). Moreover, FDR multiple
adjustment revealed that none of the parameters are associ-
ated with rs5370 genotypes. No link between EDNRA
rs5335 genotypes and BMI, BP indices, coagulogram param-
eters, fasting glucose, and blood plasma lipid profile in stroke
patients was found (Table 8).
The bioinformatical analysis of EDN1 rs5370 by the
SNPinfo tool showed that the mentioned polymorphic locus
might be located in splicing regulatory sequences recognized
by exonic splicing enhancers or exonic splicing silencers
(score—2.56). SpliceAId2 tool demonstrated that rs5370 lies
between recognized sites for SFRS9 and hnRNP H1 splicing
factors, but this SNP has no influence on their structure.
Finally, prediction analysis by PredictSNP and PredictSNP2
allowed classifying EDN1 rs5370 (Lys198Asn mutation) as
neutral (PredictSNP—neutral with 83% expected accuracy
(EA); MAPP—neutral with 68% EA; PhD-SNP—neutral
with 78% EA; PolyPhen1—neutral with 67% EA; Poly-
Phen2—neutral with 61% EA; SIFT—neutral with 67%
EA; SNAP—neutral with 50% EA; PredictSNP2—neutral
with 89% EA; CADD—neutral with 90%; DANN—neutral
with 73% EA; FATHMM—neutral with 84% EA; and Fun-
Seq2—deleterious with 62% EA).
Prediction analysis of EDNRA rs5335 by the SNPinfo tool
demonstrated that this SNP is possibly located in hsa-miR-
27a-3p and hsa-miR-27b-3p binding sites (score—153.0).
Analysis using miRDB confirmed that the EDNRA gene is
in the list of mentioned miRNA targets (target score—50).
However, PredictSNP2 results classified rs5335 mutation as
neutral (PredictSNP2—neutral with 88% EA; CADD—neu-
tral with 86%; DANN—neutral with 79% EA; FATHMM—-
neutral with 93% EA; FunSeq2—neutral with 62% EA; and
GWAWA—deleterious with 64% EA).
4. Discussion
The essence of rs5370 polymorphism is the replacement of
guanine by thymine at the 5665th position (5 exon) of the






(n = 200) PHWE P
n % n %
EDN1 rs5370
Genotypes
GG 94 47.0 118 59.0
— 0.006GT 80 40.0 72 36.0
TT 26 13.0 10 5.0
Alleles
G 268 67.0 308 77.0
0.991 0.002
T 132 33.0 92 23.0
EDNRA rs5335
Genotypes
CC 53 26.5 64 32.0
— 0.391CG 114 57.0 101 50.5
GG 33 16.5 35 17.5
Alleles
C 220 55.0 229 57.3
0.939 0.521
G 180 45.0 171 42.7
4 Disease Markers
EDN1 gene, which in turn leads to replacement of lysine by
asparagine in the 198th position of the preproendothelin-1
molecule. Several studies have shown that endothelin-1 blood
plasma concentration in T (Asn) allele carriers is higher than
in subjects with GG (Lys/Lys) genotype [24, 25]. Considering
the localization of this SNP, it can be assumed that its func-
tional effect is due to the effect on the quality or speed of
preprodendothelin-1 posttranslational modification. How-
ever, Tanaka et al. showed that the amount of ET-1 and
big ET-1 in the supernatant of Asn-type and Lys-type trans-
fected cells was similar [26]. In addition, the plasma
endothelin-1 level in patients with essential hypertension
was not different in individuals with the Asn allele and
Lys/Lys genotype. The conclusion that another SNP in
strong LD with rs5370 may provide its clinical effects was
made. Our prediction analysis of rs5370 also did not confirm
the role of this polymorphic locus in preproendothelin-1
posttranslation modification. Applying bioinformatic tools
did not allow highlighting the possible functional effects of
the mentioned SNP. Taking together experimental and pre-
diction data, it seems more likely that rs5370 is in strong LD
with another influential SNP.
The polymorphic site rs5335 is located within the
3′-UTR of the EDNRA gene and leads to cytosine/guanine
conversion at position 61,772. The functional studies of this
SNP do not exist, while several clinical studies have demon-
strated the association of this locus with increased risk of
AH development [27, 28] and level of plasma endothelin-1
[29]. On the one hand, it can be assumed that changes in
the nucleotide sequence of 3′-UTR may affect the stability
of mRNA and thus affect the amount of the receptor protein
[30]. On the other hand, this SNP may change the structure
of the miRNA binding site, as it was recently shown by Ma
et al. for miR-125a and rs12976445 polymorphism of the
Table 4: Analysis of EDN1 rs5370 and EDNRA rs5335 genotypic association with LAS.
Gene SNP Model Pc ORc (95% CI) Pa ORa (95% CI)
EDN1 rs5370
Dominant 0.012 1.657 (1.115–2.462) 0.020 1.601 (1.066–2.403)
Recessive 0.007 2.839 (1.331–6.057) 0.003 3.251 (1.492–7.084)
Additivea
0.096 1.426 (0.938–2.168) 0.198 1.328 (0.862–2.046)
0.003 3.291 (1.512–7.165) 0.002 3.637 (1.639–8.073)
EDNRA rs5335
Dominant 0.189 1.335 (0.867–2.056) 0.110 1.440 (0.921–2.251)
Recessive 0.790 0.932 (0.553–1.570) 0.767 0.922 (0.539–1.578)
Additive
0.146 1.398 (0.890–2.196) 0.078 1.522 (0.954–2.429)
0.634 1.156 (0.636–2.103) 0.545 1.210 (0.652–2.245)
SNP: single nucleotide polymorphism; CI: confidence interval; Pc: crude P value; ORc: crude odds ratio; Pa: P value adjusted for age, sex, body mass index,
arterial hypertension, type 2 diabetes mellitus, and smoking; ORa: adjusted odds ratio.
aUpper row in the additive model of inheritance—comparison
between Aa and AA genotypes; lower row—between aa and AA genotypes.
Table 5: Analysis of EDN1 rs5370 and EDNRA rs5335 genotypic association with LAS in male and female subjects.
Model Pc ORc (95% CI) Pa ORa (95% CI)
EDN1 rs5370
Female
Dominant 0.021 2.090 (1.119–3.903) 0.014 2.437 (1.202–4.940)
Recessive 0.312 2.049 (0.511–8.218) 0.086 3.824 (0.828–17.667)
Additive
0.034 2.008 (1.055–3.823) 0.042 2.135 (1.079–4.393)
0.149 2.852 (0.681–11.827) 0.018 5.634 (1.157–27.436)
Male
Dominant 0.231 1.371 (0.818–2.297) 0.236 1.375 (0.812–2.330)
Recessive 0.007 3.481 (1.404–8.635) 0.007 3.512 (1.401–8.806)
Additive
0.939 1.022 (0.581–1.800) 0.952 1.018 (0.571–1.815)
0.008 3.510 (1.382–8.913) 0.009 3.535 (1.377–9.076)
EDNRA rs5335
Female
Dominant 0.220 1.523 (0.778–2.981) 0.065 2.012 (0.956–4.230)
Recessive 0.273 1.579 (0.698–3.572) 0.351 1.515 (0.633–3.629)
Additive
0.352 1.398 (0.691–2.831) 0.105 1.921 (0.873–4.226)
0.159 1.953 (0.770–4.952) 0.111 2.256 (0.829–6.136)
Male
Dominant 0.482 1.224 (0.696–2.153) 0.514 1.210 (0.682–2.148)
Recessive 0.172 0.607 (0.297–1.242) 0.217 0.631 (0.304–1.310)
Additive
0.257 1.405 (0.780–2.529) 0.299 1.373 (0.755–2.494)
0.505 0.758 (0.336–1.710) 0.549 0.776 (0.339–1.777)
See Table 4; Pa: P value adjusted for age, body mass index, arterial hypertension, type 2 diabetes mellitus, and smoking.
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EDN1 3′-UTR [31]. In order to test these hypotheses, we used
bioinformatic prediction. Our results revealed that rs5335
might change the structure of hsa-miR-27a-3p and hsa-
miR-27b-3p binding sites, which are the possible regulators
of EDNRA expression. Future functional analysis to confirm
these results is required.
The results obtained in the present study about the link of
rs5370 (EDN1 gene) and rs5335 (EDNRA gene) polymor-
phisms with LAS showed that in a Ukrainian population,
only the rs5370 locus is associated with the development of
the mentioned disease. Regardless of adjustment for other
atherosclerosis risk factors, it was found that the risk of ische-
mic stroke development in individuals with GT and TT
genotypes is higher than in GG genotype carriers. However,
a similar study performed by Aslan et al. among the Turkish
population did not show any correlation between EDN1
rs5370 and rs10478694 polymorphisms and ischemic cere-
brovascular disease [15]. Herewith, Gormley et al. demon-
strated no association between EDN1 (rs5370), EDNRA
(−231G>A and +1222C>T), and EDNRB (G57S and 277L)
gene polymorphisms and lacunar infarction development
among English patients as well [16]. The authors of both
Table 6: Analysis of EDN1 rs5370 and EDNRA rs5335 genotypic association with LAS in subjects with and without arterial hypertension.
Model Pc ORc (95% CI) Pa ORa (95% CI)
EDN1 rs5370
Nonhypertensive
Dominant 0.262 1.500 (0.739–3.046) 0.201 1.624 (0.773–3.411)
Recessive 0.125 2.572 (0.770–8.593) 0.118 2.685 (0.778–9.269)
Additive
0.556 1.259 (0.584–2.714) 0.470 1.348 (0.600–3.029)
0.104 2.800 (0.810–9.680) 0.093 2.980 (0.834–10.650)
Hypertensive
Dominant 0.045 1.649 (1.011–2.689) 0.036 1.711 (1.035–2.829)
Recessive 0.024 3.220 (1.164–8.903) 0.008 4.102 (1.448–11.617)
Additive
0.188 1.411 (0.845–2.354) 0.212 1.400 (0.825–2.374)
0.013 3.744 (1.322–10.607) 0.004 4.743 (1.633–13.776)
EDNRA rs5335
Nonhypertensive
Dominant 0.170 1.793 (0.779–4.125) 0.132 1.962 (0.817–4.717)
Recessive 0.443 1.457 (0.558–3.806) 0.531 1.371 (0.512–3.672)
Additive
0.218 1.715 (0.727–4.048) 0.159 1.909 (0.776–4.698)
0.196 2.127 (0.678–6.676) 0.198 2.190 (0.664–7.221)
Hypertensive
Dominant 0.386 1.260 (0.747–2.126) 0.271 1.353 (0.790–2.318)
Recessive 0.325 0.730 (0.390–1.366) 0.317 0.718 (0.376–1.373)
Additive
0.214 1.420 (0.816–2.471) 0.135 1.545 (0.873–2.735)
0.788 0.970 (0.445–1.850) 0.864 0.938 (0.449–1.958)
See Table 4; Pa: P value adjusted for age, sex, body mass index, type 2 diabetes mellitus, and smoking.
Table 7: Characteristics of the LAS subjects stratified by EDN1 rs5370 genotype.
Parameter
Genotype
P value PFDRGG (n = 94) GT (n = 80) TT (n = 26)
Body mass index, kg/m2 28.1± 3.6 27.6± 3.8 28.4± 3.9 0.448 0.647
Systolic BP, mmHg 165.1± 29.3 171.3± 28.8 167.5± 25.9 0.372 0.642
Diastolic BP, mmHg 94.4± 14.9 99.3± 16.2 91.7± 13.3 0.034a 0.429
Pulse BP, mmHg 70.7± 20.2 71.9± 24.8 75.8± 22.5 0.600 0.720
Mean BP, mmHg 117.9± 18.5 123.3± 17.8 116.9± 15.2 0.099 0.429
Total cholesterol, mmol/L 4.91± 1.4 5.15± 1.6 4.74± 1.3 0.374 0.641
HDL cholesterol, mmol/L 1.02± 0.31 1.01± 0.31 0.96± 0.25 0.610 0.720
LDL cholesterol, mmol/L 3.10± 1.3 3.33± 1.5 2.89± 1.3 0.347 0.642
Triglyceride, mmol/L 1.65± 0.8 1.71± 0.8 1.58± 0.7 0.750 0.812
Prothrombin time, s 9.47± 2.0 9.38± 2.0 9.29± 2.0 0.900 0.900
Thrombin time, s 16.71± 3.7 16.49± 3.5 17.60± 4.0 0.395 0.642
Fibrinogen, g/L 4.21± 1.3 3.93± 1.2 3.64± 1.3 0.089 0.429
Fasting glucose, mmol/L 6.17± 1.7 6.06± 1.4 5.59± 1.0 0.236 0.642
n: number of cases; BP: blood pressure; HDL: high-density lipoprotein; LDL: low-density lipoprotein; PFDR: P value after false discovery rate adjustment.
aNonsignificant difference between GG and GT genotypes (P = 0 103) and between TT and GT genotypes (P = 0 087) by Bonferroni post hoc test.
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studies have concluded that genetic variation in the endothe-
lin pathway is not a risk factor for ischemic stroke.
The analysis performed in our work among subjects of
different sexes has showed that rs5370 (EDN1), but not
rs5335 (EDNRA) polymorphism, is associated with an
increased risk of LAS both among women (under dominant
and additive models) and men (under recessive and additive
models). Such data were consistent with results obtained by
Yamaguchi et al. [14], who assessed a possible association
of 202 SNPs of 152 candidate genes with atherothrombotic
cerebral infarction (ACI) in a large-scale Japanese cohort.
Authors demonstrated that EDN1 rs5370 is related to ACI
development susceptibility among women (under dominant
and additive models). In the men’s subgroup, the link with
ischemic stroke was revealed for the EDNRA −231A>G locus
(under the recessive model). At the same time, Zhang and
Sui did not reveal an association between EDN1 rs5370 and
EDNRA rs5335 polymorphic sites with ischemic stroke
development among women of the Chinese Han population
[13]. They showed that in Chinese men, the minor rs5370-
T allele increased the risk of stroke morbidity, while the
rs5335-CC genotype, on the contrary, was associated with a
low risk of ischemic stroke incident. It should also be noted
that MacClellan et al. revealed the link between EDN1
(rs1800542 and rs10478723) and EDNRB (rs4885493 and
rs10507875) SNPs and increased risk of ischemic stroke
development in Caucasian but not in African-American
women [32].
The issue of sexual difference in the endothelin system
activity is one of the key topics of the cardiovascular and uri-
nary system physiology and pathology [33]. However, the
mесhаnіsm rеsроnsіblе for the dіffеrеncе іn the endothelin
pathway gene SNP’s association with multifactorial diseases
between male and female remains unclear [14, 33]. Sex
differences obtained in our study can hardly be explained
by the protective effect of estrogens on the vascular wall,
since the studied group included mostly postmenopausal
women. It can only be said that the role of individual alleles
in ischemic stroke pathogenesis undoubtedly manifested
in a complex set of other important risk factors. Further
studies using complex analysis to draw definitive conclu-
sion are necessary.
To date, there are number of studies about the association
between endothelin system gene polymorphisms and risk
of AH and pulmonary hypertension, as well as BP indices
[5, 6, 11, 24, 34–36]. The present study revealed a high risk
of LAS development in rs5370-T allele carriers with AH,
which is inconsistent with data obtained by Yamaguchi
et al. in subgroups stratified by the presence of AH in a
Japanese population [14]. Our results also demonstrated a
possible correlation between rs5370 polymorphism and
indices of diastolic arterial blood pressure in stroke patients.
Similar results were obtained for patients with preeclampsia
[24], AH [34], and healthy individuals [37]. However, the
association of EDN1 rs5370 locus with increased risk of AH
development, as well as with different parameters of blood
pressure among Australian patients with ischemic heart
disease, was not found [11].
A significant limitation of our study is the relatively
small number of patients enrolled into the case and con-
trol groups. Therefore, some associations between rs5370
and rs5335 SNPs and the risk of LAS development, indices
of blood pressure, blood plasma lipoprotein level, and
coagulation parameters might have been missed due to a
small statistical power. Another limitation is the investiga-
tion of the link between SNPs and phenotype without an
assessment of their effects on the EDN1 and EDNRA mRNA
level and ET-1 concentration in the blood plasma. Therefore,
future case-control studies involving more patients and func-
tional studies of endothelin pathway polymorphisms effects
are required.
5. Conclusion
In conclusion, this is the first evidence about the association
between endothelin system genetic polymorphisms and
Table 8: Characteristics of the LAS patients stratified by EDNRA rs5335 genotype.
Parameter
Genotype
P value PFDRCC (n = 41) CG (n = 98) GG (n = 31)
Body mass index, kg/m2 28.7± 3.3 27.7± 3.8 27.6± 3.6 0.251 0.566
Systolic BP, mmHg 169.5± 26.9 167.3± 28.6 167.3± 32.2 0.888 0.914
Diastolic BP, mmHg 96.9± 12.7 96.7± 16.0 91.9± 17.3 0.261 0.566
Pulse BP, mmHg 72.6± 21.4 70.6± 21.6 75.3± 26.5 0.548 0.745
Mean BP, mmHg 121.2± 15.6 120.2± 18.5 117.1± 19.7 0.573 0.745
Total cholesterol, mmol/L 5.18± 1.6 5.01± 1.4 4.64± 1.4 0.257 0.566
HDL cholesterol, mmol/L 0.95± 0.31 1.02± 0.30 1.07± 0.27 0.179 0.566
LDL cholesterol, mmol/L 3.37± 1.5 3.18± 1.4 2.83± 1.3 0.235 0.566
Triglyceride, mmol/L 1.78± 0.8 1.66± 0.8 1.54± 0.7 0.383 0.671
Prothrombin time, s 9.81± 2.2 9.26± 1.9 9.31± 1.9 0.252 0.566
Thrombin time, s 16.63± 3.2 16.72± 3.6 16.96± 4.3 0.914 0.914
Fibrinogen, g/L 3.95± 1.5 4.01± 1.2 4.00± 1.3 0.878 0.912
Fasting glucose, mmol/L 6.29± 1.8 5.99± 1.3 5.89± 1.5 0.413 0.671
See Table 7.
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LAS development in a Ukrainian population. Our data
demonstrated that EDN1 rs5370 polymorphism is related
to increased risk of LAS development regardless of other
atherosclerosis risk factors. No link between EDNRA
rs5335 and risk of LAS in a Ukrainian population was
found. At present, a small number of case-control studies
about the role of rs5370 and rs5335 SNPs in ischemic
stroke development have been performed. Increasing the
number of such studies with subsequent meta-analysis is
necessary in order to draw a firm conclusion about the asso-
ciation between the mentioned polymorphisms and risk of
ischemic stroke.
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